Gene Therapy Resources

This page includes draft policy information that is still in development. You are welcome to use these materials, but please keep in mind that they may be incomplete or subject to change.

We welcome suggestions and additional resources. To share materials or feedback, please contact anna@statezebranetwork.org  

Gene - Cell Therapy

Gene therapy treats disease by correcting or replacing faulty genes. It is viewed as a breakthrough that can offer long-term or curative benefits for patients with rare and serious conditions. There is a need for sustainable access and payment models.

Party Pro / Cons and Concerns

Important Note: Remember, there are nuances that differentiate in each state. This material provides general information that can be adapted to truly align to your own state.

Democrat Party Pros
Arguments Supporting Gene Therapy Access & Policy Development
Democrat Party Pros
• Gene therapies can offer transformative or curative treatments for rare diseases, reducing suffering and long-term inequities. • Supports policies that expand insurance coverage, speed FDA review while protecting safety, and ensure Medicaid access. • Encourages federal investment in research, infrastructure, and newborn/early diagnosis programs linked to gene therapy.
Democrat Party Cons/Concerns
Arguments Raising Caution for Rare Disease Patients
Democrat Party Cons/Concerns
• High upfront costs may strain Medicaid budgets and require federal funding solutions. • Concern about equitable access if therapies are only available at select centers. • Strong focus on protecting patient privacy in genetic data used to develop or administer gene therapies.
Republican Party Pros
Arguments Supporting Gene Therapy Access & Policy Development
Republican Party Pros
• Gene therapy aligns with pro-family priorities by enabling early or curative treatment for rare genetic conditions. • Supports innovation, reduced regulatory barriers, and private-sector solutions to advance new therapies. • Early, effective treatment can reduce long-term healthcare spending and improve patient independence.
Republican Party Cons/Concerns
Arguments Raising Caution for Rare Disease Patients
Republican Party Cons/Concerns
• Very high prices raise concerns about sustainability for state Medicaid programs and private insurance markets. • Skepticism about federal mandates requiring coverage without cost controls. • Concern about government involvement in genetic data collection or oversight mechanisms tied to gene therapy monitoring.
Download pDF
Black male gene therapy
From the Patient Perspective

Gene therapy represents hope for meaningful, lasting improvement—or even a cure—after years of limited or no treatment options. Families value the potential to stop disease progression, reduce daily medical burdens, and improve long-term quality of life. At the same time, patients worry about access: whether insurance or Medicaid will cover the therapy, whether they can reach specialized treatment centers, and how long approval processes will take. The high cost, complex logistics, and uncertain long-term follow-up requirements create additional stress for families who are simply seeking a chance at a healthier future.

Talking Points
  • Guarantee coverage for FDA-approved gene therapies without new barriers.
  • Require rapid review by disease-specific experts to prevent harmful delays.
  • Maintain Medicaid access and sustainable payment models under shifting federal funding structures.
  • Ensure coverage for long-term follow-up monitoring and specialist care.
  • Support patient travel and access to centers of excellence.

 

Policy Guidelines
  1. Protect guaranteed coverage for FDA-approved gene therapies.
    Some current federal proposals could shift insurance rules or reduce benefit requirements, risking coverage gaps. Policies must ensure rare disease patients retain access to approved gene therapies without new restrictions.
  2. Prevent cost-driven denials or delays created by new regulatory frameworks.
    Gene therapies are high-cost, one-time treatments. If federal reforms increase plan discretion or reduce oversight, states must guard against insurers using utilization management to block access due to price.
  3. Require fast, specialized review processes.
    Given how time-sensitive some rare genetic conditions are, policies should mandate that gene therapy requests receive rapid review by clinicians with expertise in the specific disease—not generalist reviewers.
  4. Ensure Medicaid stability and funding eligibility.
    Federal proposals that cap or restructure Medicaid funding could make states less willing to cover gene therapy. Policies must guarantee that medically necessary gene therapies remain covered regardless of budget pressure.
  5. Encourage sustainable, innovation-friendly payment models.
    As federal reforms reshape coverage rules, states should adopt payment models (e.g., outcomes-based agreements, reinsurance, wrap-around programs) that support access without jeopardizing state budgets or stifling innovation.
  6. Protect access to specialized treatment centers.
    Gene therapy often requires care at designated centers of excellence. Policies should ensure that network adequacy standards, transportation benefits, and patient travel support are maintained if federal rules change.
  7. Ensure long-term follow-up care is covered.
    Gene therapy requires years of monitoring. Policies must preserve coverage for labs, imaging, specialist visits, and adverse event surveillance—especially important if broader reforms reduce benefit requirements.
  8. Safeguard newborns and children who rely on early diagnosis.
    Any federal or state change that affects newborn screening, genetic testing coverage, or pediatric Medicaid structure must protect the diagnostic pathways that lead to timely gene therapy.
  9. Strengthen privacy and data protections for genetic and follow-up data.
    If federal reforms expand data-sharing or reduce safeguards, states should maintain strong protections for genetic, genomic, and long-term outcome data associated with gene therapy.
  10. Ensure patient and caregiver voices guide gene therapy policy decisions.
    Given the magnitude of potential federal reforms, patient representatives must be included in state advisory groups and policy development to ensure changes do not harm access to transformative treatments.



Additional Resources

Organizations and leaders who have policy experience in this area

1-Pagers
Videos & Podcasts